Earnings ·
Reports Q3 revenue of $55.7M, up 14.5%, and reduces FY2026 operating expense growth guidance to 10.5%
SIBNSI-BONE, Inc.
SI-BONE reported third-quarter worldwide revenue of $55.7 million, a 14.5% increase from the prior year period, driven by approximately 20% U.S. procedure volume growth and strong international adoption. The company posted a net loss of $3.6 million ($0.08 per diluted share), an improvement of 20.7% compared to the previous year, alongside positive adjusted EBITDA of $3.0 million. SI-BONE reaffirmed its full-year revenue guidance of $231 million to $233 million but reduced its operating expense growth expectation for fiscal 2026 to 10.5%, down from a prior estimate of 12.0%. The firm also highlighted the receipt of FDA 510(k) clearance for iFuse Granite Onyx and favorable MS-DRG reimbursement changes for complex spinal fusion procedures. SI-BONE develops procedural solutions and implant technologies for compromised bone conditions, primarily in the spine.